NK Receptor Function in Hematopoietic Stem Cell Transplantation
NK Receptor Function in Hematopoietic Stem Cell Transplantation
批准号:
8435557
负责人:
KATHARINE C HSU
金额:
$30.76万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-01 至 2018-03-31
关键词:
Activities of Daily LivingAcute Myelocytic LeukemiaAlgorithmsAllogenicAllograftingAttenuatedBiologyBloodBone Marrow TransplantationCellsClinicalCytomegalovirusDonor SelectionEnvironmentFluorescence Resonance Energy TransferGenesGeneticGenotypeHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumanImmuneImmune systemIndividualInfectionInstructionKIR3DS1LigandsMalignant NeoplasmsMarrowMediator of activation proteinMemorial Sloan-Kettering Cancer CenterMusNatural Killer CellsOutcomePatientsPhysiciansReagentRecurrent diseaseRelapseRelative (related person)RiskShapesSiteStem cellsSystemT-LymphocyteTechnologyTransgenic MiceTransplantationViralVirus DiseasesWorkbasedesignfightinggraft vs host diseaseimprovedin vivoleukemiamortalitynovelpreventreceptorreceptor functionresponseviral leukemia
中文摘要
点击翻译按钮获取中文摘要
英文摘要
P r o j e c t 1
Allogeneic hematopoietic stem cell transplantation (HCT) is the only curative option for patients with certain
hematologic malignancies, including acute myelogenous leukemia (AML), Despite precise matching between
stem cell donor and recipient for HI_A genes, outcomes for more than half of patients remain disappointing
due to post-transplant complications, such as leukemic relapse and viral reactivation. Activation of donor
natural killer (NK) cells, key components ofthe innate immune system, can significantly prevent these
complications and Improve HCT outcomes. NK response is dictated by interactions between the NK KIR
receptors and their HLA ligands. Determining which KIR/HLA interactions most potently impact NK function
and understanding how these Interactions take place is vital to the ultimate objective of selecting donors
based on KIR and HLA to favor NK activation and improve HCT outcomes. The first aim ofthe proposal uses
a unique transgenic mouse system and FRET technology to demonstrate that inhibitory KIR molecules
interacting with HLA presented by adjacent cells (trans) as well as by the NK cell itself (cis) can both shape
NK function. These results are directly relevant to predicting NK response in HLA-matched and mismatched
HCT. The second aim is to show that the activating KIR2DS1 and KIR3DS1 contribute in an HLA-dependent
manner to the functional capacity of the cell, explaining findings that KIR2DS1 in patients with the KIR ligand
HLA-C1 is associated with lower relapse following HCT and that KIR3DS1 is associated with lower CMV
reactivation. Findings from Alms 1 and 2 will support the concept that to capture NK activation In HCT, one
must minimize NK inhibition. A novel donor selection algorithm based on KIR/HLA genotypes to maximize
NK activity and improve HCT outcomes Is presented. The third aim seeks to apply this algorithm to donor
selection, comparing outcomes post-selection with historic outcomes of HCT patients. Successful
demonstration ofthe algorithm's feasibility and clinical impact will potentially change donor selection from an
HIA-based strategy to a KIR/HLA-based strategy that will take advantage of innate immune effects against
infection and relapse without increasing the risk of T-cell alloreactivity and graft-versus-host disease.
RELEVANCE (See instructions):
Natural killer (NK) cells are a vital component ofthe body's immune system, protecting the individual from
viral infections and from developing cancer. This proposal is designed to help bone marrow transplant
doctors understand what controls NK cells so that they can use NK cells and the immune system to fight viral
infections and leukemia.
PROJECT/PERFORIVIANCE SITE(S) (if additional space is needed, use Proiect/Perfonnance Site Fomiat Page)
Project/
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome
-
批准号:10390447
-
项目类别:
-
资助金额:$70.98万
-
财政年份:2021
-
负责人:KATHARINE C HSU
-
依托单位:
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
-
批准号:10322105
-
项目类别:
-
资助金额:$60.84万
-
财政年份:2021
-
负责人:KATHARINE C HSU
-
依托单位:
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome
-
批准号:10590647
-
项目类别:
-
资助金额:$73.31万
-
财政年份:2021
-
负责人:KATHARINE C HSU
-
依托单位:
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
-
批准号:10534187
-
项目类别:
-
资助金额:$59.59万
-
财政年份:2021
-
负责人:KATHARINE C HSU
-
依托单位:
Natural killer cell and T-cell crosstalk in CMV infection
-
批准号:9398188
-
项目类别:
-
资助金额:$30.63万
-
财政年份:2017
-
负责人:KATHARINE C HSU
-
依托单位:
KIR and HLA in cis and trans cooperatively shape human NK education
-
批准号:9160652
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2016
-
负责人:KATHARINE C HSU
-
依托单位:
KIR and HLA in cis and trans cooperatively shape human NK education
-
批准号:9310137
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2016
-
负责人:KATHARINE C HSU
-
依托单位:
Phase I study humanized 3F8 MoAb (IND 112594) and NK cells (IND BB-13399) for neuroblastoma
-
批准号:9488351
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2016
-
负责人:KATHARINE C HSU
-
依托单位:
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes
-
批准号:9271228
-
项目类别:
-
资助金额:$57.34万
-
财政年份:2015
-
负责人:KATHARINE C HSU
-
依托单位:
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes
-
批准号:8865414
-
项目类别:
-
资助金额:$42.1万
-
财政年份:2015
-
负责人:KATHARINE C HSU
-
依托单位:
Combination immunotherapy for neuroblastoma: model of innate tumor immunity
-
批准号:8508896
-
项目类别:
-
资助金额:$34.4万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma
-
批准号:8217684
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma
-
批准号:8544192
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma
-
批准号:8730476
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Combination immunotherapy for neuroblastoma: model of innate tumor immunity
-
批准号:8731836
-
项目类别:
-
资助金额:$35.49万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Combination immunotherapy for neuroblastoma: model of innate tumor immunity
-
批准号:8373670
-
项目类别:
-
资助金额:$36.44万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:7743072
-
项目类别:
-
资助金额:$42.08万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:8197289
-
项目类别:
-
资助金额:$41.65万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:7383207
-
项目类别:
-
资助金额:$42.13万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:7536389
-
项目类别:
-
资助金额:$42.08万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
海外基金